Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments Mar 31, 2025
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants Dec 20, 2024
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Dec 5, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments Nov 8, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock Oct 30, 2024
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock Oct 28, 2024
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Oct 24, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 Oct 22, 2024
